Compare GSK plc (GSK) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs RLX Technology Inc — how do they compare? GSK plc trades at $46.55 (market cap $91.88B), while RLX Technology Inc trades at $1.74 (market cap $2.10B). The key difference: GSK plc is far larger — about 43.8× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and RLX Technology Inc for 35 Days on average.
| GSK | RLX | |
|---|---|---|
Market Cap | $91.88B | $2.10B |
Volume | 7,730,529 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $2.57 |
52-Week Low | $43.24 | $1.68 |
Typical Hold Time | 93 Days | 35 Days |
Enterprise Value | $111.88B | $832.26M |
Dividend Yield | 3.9% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
RLX Technology trades at $1.735, up 0.29% with bearish technical signals despite recent 52-week lows. The company shows solid fundamentals with $3.62B revenue, 21.87% net margin, and attractive valuation at P/E 15.46 and P/B 0.91. Recent earnings missed expectations but international expansion drives growth, with 70% revenue now from overseas markets. Cash flow trends improved significantly from -$99M in 2025 to $881M projected for 2026.
RLX presents a value opportunity with discounted valuation and strong international growth, though technical weakness and earnings misses warrant caution. The single analyst coverage maintains Hold rating, reflecting uncertainty amid expansion execution risks and regulatory challenges in the e-vapor industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
